Bradley L. Radoff Urges Redwood Trust’s Board of Directors to Explore a Sale
Bradley L. Radoff today issued the following open letter to the Board of Directors of Redwood Trust, Inc. (
NYSE: RWT).
Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena
Bradley L. Radoff, a significant shareholder of Cerus Corporation (
NASDAQ: CERS) (“Cerus” or the “Company”), today announced his intention to withhold support for the Company’s two director nominees at the upcoming 2026 annual meeting in the below open letter to shareholders.
Bradley L. Radoff Announces Vote AGAINST the Reelection of Marston’s PLC’s Non-Executive Directors
Bradley L. Radoff, who collectively with his affiliates owns approximately 3% of the outstanding common shares of Marston’s PLC (LSE: MARS) ("Marston’s" or the "Company"), today issued the following open letter to shareholders regarding Mr. Radoff’s decision to vote against the reelection of the Company’s five non-executive members of the Board of Directors (the “Board”) at the upcoming Annual General Meeting (“AGM”): Chair Ken Lever, Octavia Morley, Rachel Osborne, Bridget Lea and Sir Nick Varney.
Concerned Shareholder Bradley L. Radoff Urges Quipt Home Medical’s Board of Directors to Pursue a Value-Maximizing Sale
Bradley L. Radoff, who collectively with his affiliates owns approximately 4.9% of the outstanding common shares of Quipt Home Medical Corp. (
NYSE: QIPT) ("Quipt" or the "Company"), today issued the following statement regarding the manner in which the Company’s Board of Directors (the “Board”) has failed to capitalize on apparent acquirer interest:
Bradley L. Radoff Issues Letter to Enviri’s Board of Directors Regarding the Need for Meaningful and Urgent Change
Bradley L. Radoff, who collectively with his affiliates owns a significant equity stake in Enviri Corporation (
NYSE: NVRI) ("Enviri" or the "Company"), today issued the below open letter to the Company’s Board of Directors (the “Board”) regarding the need for immediate leadership and structural changes following a prolonged period of negative returns and underperformance.
Bradley L. Radoff Reiterates Call for GSE Systems’ Board Chair Kathryn O’Connor Gardner to Disclose 2025 Projections
Bradley L. Radoff, who collectively with his affiliates owns approximately 9.9% of the outstanding shares of GSE Systems, Inc. (
NASDAQ: GVP) (“GSE” or the “Company”), today issued the below follow-up letter to the Chair of the Company’s Board of Directors (the “Board”), Kathryn O’Connor Gardner, in response to the Company’s filing of an amended merger agreement with Pelican Energy Partners (“Pelican”).
Bradley L. Radoff Urges GSE Systems’ Board Chair Kathryn O’Connor Gardner to Release 2025 Projections
Bradley L. Radoff, who collectively with his affiliates owns approximately 9.9% of the outstanding shares of GSE Systems, Inc. (
NASDAQ: GVP) (“GSE” or the “Company”), today issued the below open letter to the Chair of the Company’s Board of Directors (the “Board”), Kathryn O’Connor Gardner, to urge the Board to provide the market with customary disclosures regarding the Company’s forward-looking projections.
Bradley L. Radoff Issues Open Letter to GSE Systems’ Board of Directors to State Opposition to Proposed Sale to Pelican Energy Partners
Bradley L. Radoff, who collectively with his affiliates owns approximately 9.9% of the outstanding shares of GSE Systems, Inc. (
NASDAQ: GVP) (“GSE” or the “Company”), today sent the below letter to GSE Systems’ Board of Directors (the “Board”) indicating its opposition to the proposed take-private merger with Pelican Energy Partners (“Pelican”).
Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support
Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio”), today issued the following open letter to the Boards of Directors (collectively, the “Boards”) of Sesen Bio and Carisma Therapeutics Inc. (“Carisma” and together with Sesen Bio, the “Companies”):
Investor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma Merger
Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today issued the following open letter to the Company’s Board of Directors (the “Board”) regarding the proposed merger with Carisma Therapeutics Inc. (“Carisma”):
Investor Group Reiterates Intent to Vote AGAINST Sesen Bio’s Value-Destructive Merger with Carisma
Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today reiterated their intent to vote AGAINST the Company’s proposed merger with Carisma Therapeutics Inc. (“Carisma”) through the following statement:
